(UroToday.com) Daniel Pryma, MD, discussed the current status of theranostics in 2020 as part of the recent advances in nuclear medicine theranostics for cancer session at the 2020 ASCO virtual education program. In the United States, there are varying regulatory constraints with different rules for compassionate use, reimbursement, and radiation safety. Additionally, theranostics in the United States have to undergo a rigorous regulatory process, many agents are unavailable for clinical, however, those that are available do have robust data. As follows is a list of FDA approved and investigational radiopharmaceutical therapies: